BACKGROUND AND SIGNIFICANCE
The enterprise of clinical trials in the USA faces many challenges, according to the Institute of Medicine. 1 The Patient Centered Outcomes Research Institute is investing over US$90 million in PCORnet, which seeks to reimagine the country's clinical research infrastructure and make progress to overcome these challenges. 2 Clinical data analytics platforms will be used at over 100 sites in all 50 states to more easily match eligible patients to trials and to perform large scale comparative effectiveness research aided by retrospective clinical data. These goals agree with previous achievements associated with clinical data analytics platforms: increased local research funding, decreased cost to recruit patients to clinical trials, 3 unprecedented access to local data to answer challenging questions, 4 and distributed research across previously disconnected populations. 5 Informatics for Integrating Biology and the Bedside (i2b2) is an open source freely available clinical data analytics platform funded by the National Institutes of Health. It is implemented at over 100 sites nationwide, including over one-third of PCORnet's sites. [6] [7] [8] It has an active community of users and contributors, and a flexible data model that supports diverse implementations. Currently, six i2b2 networks share aggregate level data for population level research, 9, 10 and i2b2 components specifically designed for clinical trial recruitment are in development. 11 However, even with open source solutions like i2b2, the barrier to entry for implementing a clinical data analytics Correspondence to Dr J G Klann, Laboratory of Computer Science, Massachusetts General Hospital, One Constitution Center, Charlestown, MA 02129, USA; jeff.klann@mgh.harvard.edu platform is too high in some cases. Every implementation of i2b2 must define a custom approach to extract data from clinical systems, normalize it, and import it into i2b2. This process is called extract, transform, and load (ETL). This can be a complex expensive development process that is likely out of scope for small practices. (And in fact, most i2b2 installations are affiliated with large academic medical centers.
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) Small practices could benefit from i2b2 in at least two significant ways. One, it would allow them to be part of clinical trial recruitment networks at low cost, which provides economic benefit to practices and empowers patients with the ability to contribute to research. There are multiple initiatives to build such networks of i2b2 repositories, including those of Patient Centered Outcomes Research Institute and the National Institutes of Health, which will be used to accrue for clinical trials. Two, i2b2 provides a low cost system for physicians to study their own patient population. This allows a wide variety of 'on the fly' research questions, such as pragmatic validation of complex treatment decisions 4 or studying local trends for quality measurement or collective intelligence. 13, 14 Also, chronic disease registries typically do not have access to their patients' medical record data and must rely on patients' manual data entry. PCORnet includes 18 Patient Powered Research Networks (PPRNs) that represent patients with chronic disease, but less than half have an active registry, 15 and a recent survey confirmed that most of the registries rely exclusively on patient reported data. PCORnet's long term goal is for PPRNs to import their patients' electronic health record (EHR) data, which will enhance the networks' research capabilities, but there is no plan to achieve this at present.
Here we present a straightforward reusable ETL approach that will allow both disease registries and small practices to more easily implement i2b2. It takes advantage of requirements mandated by stage 2 of the Meaningful Use incentive program (MU2): healthcare facilities are required to produce consolidated clinical document architecture (C-CDA) patient care summaries. 16, 17 All certified EHR systems will shortly be able to produce these machine readable documents with up to the minute patient information in standard terminologies. For example, Partners Healthcare (Boston, Massachusetts, USA) is building the capacity to generate at least 75 000 documents per day. Furthermore, patients must have access to visit summary information in MU2, and the popular Blue Buttonþ initiative is enabling individuals to access their own C-CDA documents. [18] [19] [20] Meaningful Use stage 3 is expected to require support for Blue Buttonþ and might include a requirement for healthcare systems to submit C-CDAs to disease registries. 19 ,21
OBJECTIVE
To demonstrate the ability to populate research databases from C-CDA documents, we created an i2b2 repository at Partners Healthcare using just C-CDA documents. We validated our ability to perform clinical research tasks with this repository using i2b2's graphical query tool 6, 22 and the SMART patient centric view. 23 This proof of principle is readily extensible to other environments with C-CDAs, providing a straightforward approach for low volume data import for patient registries and small practices. An overview of this approach and its expected use cases is shown in figure 1 . Reaching this objective involved developing a flexible i2b2 extension to import C-CDA documents and new ontology trees for the standard C-CDA terminologies. These components will soon be available as open source tools on the i2b2 wiki. 24 
MATERIALS AND METHODS
Design i2b2 is a flexible relational data model and an extensible set of web services to interact with that data model. i2b2 web services are logically organized into sets of independent software components, known as cells. These cells interact through web service calls, and together these cells make up the i2b2 'hive'. Many optional cells have been developed that extend the functionality of i2b2. i2b2 provides several standard user interaction motifs powered by these cells, including a graphical query builder used to find research cohorts and a patient 'EHR view' powered by SMART apps. 23 These will be packaged together in the 'i2b2 clinical trials' platform.
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The underlying data model is a star schema design 25 in which one large fact table stores most clinical observations. An observation can be any atomic fact, such as a diagnosis, procedure, medication, or even a computed value (eg, length of stay). Each observation may consist of several rows of information: the basic fact (eg, 'diabetes mellitus') and modifiers that provide additional context (eg, 'admit diagnosis'). Each fact and modifier is associated with a code that is often used to define the code and coding system (eg, 'ICD9:250.6'). To create the 'star', there are several 'dimension' tables that provide additional information about the facts, such as the patient, encounter, and provider dimensions.
Additionally, the set of known facts is navigable by ontology trees that are also stored in the data model. i2b2 provides several trees, others have been defined by individual i2b2 sites and projects that use i2b2, and they can be imported from the NCBO BioPortal. 26 i2b2 can assign pseudoidentifiers to patients while keeping a mapping to the original medical record number (MRN) stored securely, separately from the rest of the patient data. This allows query results to be de-identified while allowing reidentification in appropriate circumstances. This is important in the present use case because i2b2 pseudoidentifiers are insufficient for C-CDA retrieval.
i2b2 exchanges clinical data among cells and applications using the i2b2 patient data object (PDO) XML format. This is a reflection of the underlying data model. PDO groups clinical data into groups of facts, with optional sections for dimension tables and patient mapping. i2b2's clinical research chart (CRC) cell includes a loader component that supports data import through the PDO.
This cell provides a web service that takes as input a list of patient MRNs. The cell calls a configurable command to retrieve a C-CDA for each patient MRN. This design allows each i2b2 site to define its own particular method for retrieving a C-CDA-they might exist in a database, in a folder on the local disk, or through an enterprise web service. On retrieving each C-CDA, SETL converts it to a PDO and sends it to the CRC loader for import into i2b2. The CRC loader automatically assigns a pseudoidentifier to the patient if one does not exist, and the actual MRN is securely stored separately. Finally, the SETL cell generates a report about the number of new patients, observations, and encounters added to the repository. For this first version, we convert demographics, encounters, diagnoses, and medications. Figure 2 (left) shows this data flow, with the external command configured for Partners Healthcare continuity of care document (CCD) factory (see Data source below).
We are finalizing ontologies to support queries on the imported data. We use the following: for demographics, a subset of the existing i2b2 demographics ontology; for diagnoses, a SNOMED hierarchy of clinical findings converted from the NCBO BioPortal; and for medications, an RxNorm hierarchy organized by Veterans' Administration drug class. We generated the RxNorm terminology using mappings present in the Unified Medical Language System that connect Veterans' Administration drug classes with RxNorm generic and brand name medications.
The most problematic part of this ETL workflow is processing C-CDA documents. C-CDA is a set of restrictions on the extremely expressive clinical document architecture (CDA). The CDA is a specialization of the very broad HL7v3 Reference Implementation Model (RIM). The RIM is a general information model for expressing healthcare information through objects such as acts and the relationships between them. Although this design is very elegant theoretically, in practice an immense amount of work has gone into limiting expressivity to support computability and data exchange. Even at the level of the MU2 templates, there is room for differences of opinion on document structure, and implementations vary from site to site. C-CDA is also difficult to parse or understand because it is so complex and deeply nested. As an example, the first problem in a patient's problem list is eight levels deep in the XML hierarchy. The XPath expression is: We used Open Health Tools (OHT) to navigate the C-CDA XML hierarchy. 27 OHT is a non-profit trade association responsible for growing and managing a diverse set of tools for healthcare interoperability. A particularly innovative emerging solution in OHT is the Model Driven Message Interoperability (MDMI) project, 28 which utilizes an existing Object Management Group (OMG) standard for message exchange and applies it to healthcare. Leading experts in the banking industry developed MDMI for translation of data into a variety of can use the C-CDA documents they already produce to populate an i2b2 data repository. Right: Patients will be able to export their C-CDA from healthcare systems through Blue Buttonþ, which they can donate to disease registries for research. Bottom: i2b2 can then be used to study both cohorts and individual patients, through the i2b2 query tool and SMART apps, respectively (see figure 4) . proprietary formats. The innovation of MDMI over other message translation tools is that it is model based. MDMI defines a central 'referent index' that lists all of the data elements that a healthcare document could include. Maps can be written that define a message model. Then, particular message formats can be translated by these maps to and from the referent index, without concern about the ultimate inputs and outputs.
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OHT-MDMI is an open source project; its first public release is scheduled to be available shortly. 28, 29 We programmatically integrated OHT-MDMI into the SETL cell to automatically translate input C-CDA documents into PDO. To accomplish this, the OHT-MDMI group provided us with a MU2 compliant C-CDA map that translates to and from the core referent index. Our message translation work was then to develop a map that translates the referent index into i2b2 PDO. We developed this using the included graphical map editor. This helped us navigate the complex structure of C-CDA. This integration is shown in figure 3 (right) .
For a site to implement our ETL process, the primary task would be to use the same graphical editor to modify the mapping of the source C-CDA for local variants. This does not require knowledge of the i2b2 PDO format. These changes are straightforward, and the map editor is intended for site administrators, not software developers. For an example of such a change, see the second paragraph of 'Implementation' below.
Data source
We used the Partners Healthcare CCD factory as our data source, which dynamically compiles patient information into MU2 compliant C-CDAs and is expected to handle capacities of over 75 000 documents generated daily. 30 We wrote an adapter program to communicate with the CCD factory and retrieve C-CDAs. Because MU2 does not require encounter histories or encounter notes for the current C-CDA profiles, we retrieved those from an outpatient notes service and added these to the C-CDA document dynamically via our adapter. This study was approved by the institutional review board at Partners Healthcare.
RESULTS

Implementation
For this initial release, we focused on importing patient information that was of high value for clinical trial recruitment: encounters, problems, medications, and demographics. 31 We implemented the SETL cell in i2b2 1.7 as a JBoss 7 web (4) are sent to the data repository cell for storage, where MRNs are replaced by a unique pseudoidentifier. Finally (5, 6) a report on import errors and statistics is generated and returned to the user. ETL, extract, transform, and load. Right: The SETL cell embeds the Open Health Tools Model Driven Message Interoperability (MDMI) engine, which converts between healthcare data formats.
service, like the other cells in the i2b2 hive. We also updated the SMART-i2b2 and CRC cells to fully support i2b2 1.7. We implemented the Partners Healthcare CCD adapter as a .NET program (that corresponds with the security model of the Partners Healthcare CCD factory) that can be called remotely over encrypted SSH within Partners' firewall.
We were able to use OHT-MDMI's C-CDA map without modification for all the required entries in the aforementioned sections of the C-CDA. This map does not yet implement the optional sections of the C-CDA, and Partners Healthcare still uses the older C32 specification for some of these elements. Therefore, we used the MDMI map editor to add several Partners specific elements, such as provider information. To change the location of elements already in the map, we would simply navigate to that element in the editor's referent index, open the associated syntactic element, and change the XPath to reflect its location in the document. Because provider information is optional, it was not in the map, so it required an extra step. To add provider names for problems, we created a new syntax element and populated it with the appropriate XPath. Then we used an editor wizard to link it with a new semantic element that in turn links to ProblemPerformerName in the referent index. The total time to make this change was less than 5 min.
We then developed an i2b2 map with assistance from OHT-MDMI. MDMI maps contain two components: a set of semantic elements-the distinct blocks of information that have meaning in the data model; and one or more syntactic structures-descriptions of how the semantic elements precisely map to the output data format (eg, XML). MDMI provided an XML schema import tool that allowed us to create the syntax structure from our i2b2 PDO definition. We used their map editor to define semantic elements that are 'transferred' from the source data model. Table 1 summarizes the semantic elements in our i2b2 map. The key elements are the observations, which transfer clinical data from the C-CDA for storage in i2b2. All observations except encounters are mapped as a single core fact (eg, medication). We have not added modifiers to transfer additional detailed information (eg, medication route and frequency) because to do so efficiently will require a feature that will appear in the next release of MDMI (winter 2014).
All of the i2b2 components and ontologies described here are available separately. The updated CRC cell will be part of future i2b2 1.7 service packs. The remaining i2b2 components (SETL cell, upgraded SMART-i2b2 cell, and ontologies) will be released on the i2b2 wiki. 32, 33 OHT-MDMI's map editor will be available on the OHT website. 29 We expect site specific changes will only require modifying the C-CDA and i2b2 maps using the OHT-MDMI map editor.
Evaluation
We deployed i2b2 1.7 and our additions on a 3 GHz Intel Xeon virtual machine (VM) inside the secure Partners environment. The VM had 2 GB of RAM and 15 GB of disk space. We created an i2b2 project on the physical SQL Server database (8 processors, 64 GB RAM) used for many of our internal research projects, which we directed our VM to use. To evaluate the import process, we loaded 150 patients into i2b2 from C-CDA documents. We measured the speed and information loaded, and we verified the ability to perform both cohort queries and individual patient review via SMART apps. Because we used our standard production environment, we imagine this is a good average case test of our components.
We used the Partners data repository to select patients between 18 
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on each of those patients since January 1, 2013 was 186 (SD 415). Therefore, to choose 'average' patients, we selected all of these patients between the average and 1 SD greater than the average (between 186 and 601 observations), resulting in 80 501 patients. We randomly chose 150 of these patients. We removed five of these patients from consideration: in two cases, Partners' CCD factory could not generate a C-CDA and in the remaining three the supported sections of the C-CDA were empty or contained only invalid dates and unmapped codes.
We imported problems, demographics, medications, and encounter notes for the remaining 145 patients, and recorded both number of observations imported and the time to import them. We also re-ran the import without notes to determine the impact of importing notes. This is instructional for implementers, because notes are not required in the MU2. Server and service load impacted import speed, but we ran our import after 17:00 to minimize this effect. Results are shown in table 2 and figure 3. Each C-CDA was imported in, on average, 3 s without notes and 10 s with notes. Partners' CCD factory added an additional overhead of 9 6 5 s/patient. Problem and medication lists were on average five items long and the majority of items were added in the past 3 years (57% for problems, 94% for medications).
We analyzed the completeness of our ontologies against the imported data by comparing the set of imported SNOMED and RxNorm codes to those in our ontologies. We found that 95.9% of the problem list codes are listed in our SNOMED ontology and 97.3% of the medication list codes are listed in our RxNorm ontology. For RxNorm, six of the missing codes were drug combination packs such as ethinyl estradiol/etonogestrel that we are currently adding. The remainder were obsolete or invalid codes. In SNOMED, the missing codes were not diagnoses but procedures or clinical statements (like 'family history'). Our current SNOMED ontology includes only clinical findings, but we have developed ontologies for other parts of SNOMED that we are considering including. At present, the i2b2 workbench provides an 'edit terms' view that is available for adding additional codes to existing ontology trees as necessary.
We also selected three random test patients generated by Partners Healthcare. Using the same methodology described above, we imported these three test patients for indepth testing. We created several cohort queries using the ontologies and verified that the counts returned were the same as the same queries run against the imported database. For example, we performed a query for all patients using a simvastatin 40 mg tablet and found that this number was equivalent to the number of patients with a fact entry for 'RXNORM:198211'. Finally, we ran SMART apps to view information about individual imported patients to verify that notes, medications, and problems displayed correctly. Figure 4 shows a patient count query on the imported data and the note list of a test patient viewed in a SMART app.
DISCUSSION
We successfully generated an i2b2 data repository from 145 C-CDA documents representing 'average' patients at Partners Healthcare, importing approximately 17 000 facts in about 24 min. These patients had an average medication list and problem list of five entries each, with the majority of data coming from notes. We were able to explore this repository with the graphical query tool and view patient notes, medications, and diagnoses with the SMART apps we previously developed for i2b2. 23 This experiment demonstrates that this standards based import approach can successfully populate an i2b2 repository using only C-CDA documents. Our approach combines existing open source tools with new tools and ontologies that we are also in the process of releasing into open source. Our tools are readily extensible to other sites with minimal technical work: only the MDMI maps need to be edited to match local C-CDAs.
Our evaluation represents a reasonable test case for target users: small practices and disease registries such as the PCORnet PPRNs. While not a replacement for the custom direct to database ETL scripts written for site specific high volume import, we expect our approach is more than sufficient for these low volume environments. Small practices can leverage their investment in MU2 compliant EHR technologies that must already produce these C-CDA documents. Disease registries can set up a research repository from patients' C-CDAs, and patients are increasingly gaining access to these documents due to MU2 requirements.
Limitations and future directions
The primary limitation of our approach is that implementations of C-CDAs are variable, and the documents might be incomplete or inaccurate snapshots of patient care. For disease Each C-CDA took, on average, 3 s to import without notes and 10 s with notes, not including the Partners specific CCD factory generation time.
CCD, continuity of care document; C-CDA, consolidated clinical document architecture. registries in particular, C-CDAs required by MU2 might not be granular enough to perform meaningful research. The utility of C-CDA data for research and trial recruitment is largely untested, but concerns exist. A recent MITRE report found that the majority of codes referenced by Meaningful Use Clinical Quality Measures are not present in the clinical data in C-CDAs collected by the Massachusetts eHealth Collaborative. 34 Practically, implementation of our approach in other C-CDA environments could prove challenging. At Partners, OHT-MDMI's map worked without modification for all required sections of the C-CDA. A recent study showed that across 17 MU2 certified vendor systems, C-CDA documents were generally structurally compatible. This is a reasonable finding, because all certified systems must produce C-CDA documents that pass a structural validation test. However, this study found minor 
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Klann JG, et al. J Am Med Inform Assoc 2015;22:370-379. doi:10.1136/amiajnl-2014-003040, Research and Applications structural differences and a range of semantic issues (eg, improper dates, codes, or coding systems). 35 We expect a reduction in these incompatibilities as C-CDA becomes more widely implemented, but the number of map changes required at sites is presently unknown.
At present, our work supports only demographics, encounter notes, medications, and problems, because these are most important in screening for clinical trial eligibility. Other sections of the C-CDA, such as laboratory results and procedures, can be very important for other research questions. Supporting the remainder of the C-CDA will involve expanding the i2b2 map and developing new ontologies for the remaining sections. To import the full richness of C-CDA, the OHT-MDMI map will need to support the optional elements in the standard, and the i2b2 map will need to utilize a C-CDA specific ontology like the one previously developed for Query Health. 36 Further ontology development is needed. A national collaboration to coordinate standard ontology development is now underway as part of PCORnet. This collaboration is presently developing common ontologies to enable interoperability and implementation of the PCORnet Common Data Model, with an eye to expanding to Meaningful Use standards.
CONCLUSION
This work successfully paves a standards-based pathway to reuse Meaningful Use required CCD for clinical research. This could give PCORnet's PPRNs a method to import their patients' EHR data, and it lowers the barrier to entry for small practices to participate in clinical research initiatives and to study their own patient populations. The tools we have developed and validated are open source extensions to the i2b2 clinical data analytics platform that will be available shortly, and are designed to be easily extensible to other environments.
